Seegene Inc
상단으로
Contact Us

Product News You can check out the latest product information

  • Obtained CE-IVD marking for Allplex™ 2019-nCoV Assay

    Seegene has received CE-IVD mark under European Union on In Vitro Diagnostics Medical Devices for Allplex™ 2019-nCoV Assay.          This assay is a multiplex Real-time PCR assay that detects and identifies the new coronavirus named as COVID-19 using three target genes,  E gene, RdRP gene and N gene. Allplex 2019-nCoV assay realizes increase of throughput using test in one tube and automation system.

    Feb 13, 2020｜ Allplex™ 2019-nCoV assay

  • Obtained CE-IVD marking and MFDS approval for Allplex™ PneumoBacter Assay

    Seegene has received CE-IVD mark under European Union on?In Vitro?Diagnostics Medical Devices, and received approval from Korean Ministry of Food and Drug Safety (MFDS) for Allplex™ PneumoBacter Assay. This assays?is a Multiplex Real-time PCR assay that detects and identifies 7 major respiratory bacteria associated with pneumonia. Based on Seegene's proprietary MuDT™ technology, this assay reports multiple Ct values of each pathogen in a single channel.

    Feb 20, 2019｜ Allplex™ PneumoBacter Assay

  • Obtained approval of MFDS for Allplex™ Respiratory Panel3

    Allplex™ Respiratory Panel 3 has received approval from Korean Ministry of Food and Drug Safety (MFDS).   This assay is a One-step real-time RT-PCR assay to detect simultaneously Bocavirus, Rhinovirus and three Coronaviruses (NL63, 229E, OC43) which cause respiratory infections in a single tube.

    Nov 24, 2016｜ Allplex™ Respiratory Panel 3

  • Obtained approval of MFDS for Allplex™ Respiratory Panel1

    Allplex™ Respiratory Panel 1 has received approval from Korean Ministry of Food and Drug Safety (MFDS). This assay is a One-step real-time RT-PCR assay to detect simultaneously Flu A, Flu B, RSV A and RSV B with Flu A subtyping in a single tube, which enables appropriate antiviral drug treatments

    Sep 01, 2016｜ Allplex™ Respiratory Panel 1

  • Obtained CE-IVD marking for Anyplex™ MERS-CoV Real-time Detection

    Anyplex™ MERS-CoV(upE) Real-time Detection,  Anyplex™ MERS-CoV (upE&orf1a) Real-time Detection Anyplex™ MERS-CoV (upE) Real-time Detection is a multiplex real-time one-step RT-PCR assay targeting upstream of the E protein gene (upE) for detection of MERS-CoV. The assay for the upE target is considered highly sensitive and is recommended for screening of MERS-CoV. Anyplex™ MERS-CoV (upE&orf1a) Real-time Detection is a multiplex real-time one-step RT-PCR assay targeting upstream of the E protein gene (upE) and orf1a gene for screening and confirmation of MERS-CoV.

    Jul 27, 2015｜ Anyplex™ MERS-CoV(upE & orf1a) Real-time Detection

  • Launched Allplex™ Respiratory Full Panel Assay

    Multiplex One-step RT Real-time PCR assay for reliable test results Allplex™ Respiratory Full Panel assay that composed of 4 different panels is a multiplex One-step RT Real-time PCR assay to detect and identify 16 viruses, 7 bacteria and 3 Flu A subtypes in patient’s specimens. Based on Seegene’s proprietary MuDT™ technology, this assay makes it possible to report individual Ct value of multiple pathogens in a single channel on real-time PCR instrument.Allplex™ Respiratory Full Panel AssayComprehensive assay for the detection and identification of 26 pathogens using One-step RT Real-time PCR

    Mar 23, 2015｜ Allplex™ Respiratory Panel Assays

  • Launched Anyplex™ II RB5 Detection

    Anyplex™ II RB5 Detection1Simultaneous detection of 5 Respiratory bacteriaAnyplex™ II RB5 Detection detects 5 respiratory bacteria in a single real-time PCR. Mycoplasma pneumoniae (MP), Chlamydophila pneumoniae (CP), and Legionella pneumophila (LP) are the most common causes of atypical pneumonia. As these atypical pathogens do not respond to β-lactam antimicrobial therapy commonly used for bacterial community-acquired pneumonia (CAP), accurate diagnosis beyond clinical assessment is critical for determination of optimal and effective treatment. Anyplex™ II RB5 Detection has been developed using Seegene's proprietary TOCE™ Technology as a rapid and simple multiplex molecular diagnostic to simultaneously detect and differentiate CAP-related pathogens with high sensitivity and specificity. In addition, Anyplex™ II RB5 also detects and differentiates two causative agents of whooping cough, the commonly detected Bordetella pertussis(BP) as well as the less common but vaccination-ineffective Bordetella parapertussis(BPP). In addition to enabling detection and differentiation of these 5 pathogens, responsible for the respiratory bacteria infections, Anyplex™ II RB5 providing valuable information for more precise diagnosis, effective treatment and clinical follow-up.

    Aug 31, 2012｜ Anyplex™Ⅱ RB5 Detection

  • Obtained CE-IVD marking for Anyplex™ II RV16 Detection

    Anyplex™ II  RV16 DetectionSimultaneous detection of 16 respiratory viruses Seegene's Anyplex™ II  RV16 Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Dec 23, 2011｜ Anyplex™Ⅱ RV16 Detection

12345